AI-generated analysis. Always verify with the original filing.
Outlook Therapeutics, Inc. closed a best-efforts public offering on March 25, 2026, of 20,000,000 shares of common stock and accompanying warrants to purchase 20,000,000 shares at a combined price of $0.25, raising approximately $5.0 million in gross proceeds and $4.0 million in net proceeds. This financing provides capital but involves substantial dilution from new shares and exercisable warrants.
Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On March 23, 2026, Outlook Therapeutics, Inc. (the “Company”) commenced a best-efforts public offering (the “Offering”) of its common stock and ac
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 4.1 Form of Warrant. 4.2 Form of Placement Agent Warrant. 5.1 Opinion of Cooley LLP. 10.1